Table 1

Demographic, genetic and biochemical data

ADMCICON
HealthyHeadachePsychiatricPD
Demographics
 PatientsNo.982150212819
 FemaleNo.59621111510
 MaleNo.39152910139
 Age (years)Median (IQR)72 (64–77)72 (66 to 77)66 (59–70)58 (51–64)59 (46–64)68 (62–73)
 MMSE scoreMedian (IQR)23 (19–25)28 (27 to 29)NANA28 (27–29)NA
 MoCA scoreMedian (IQR)NANA30 (28–30)NANA29 (27–29)
Genetic
 APOE ε4 −/−No.124NANA6NA
 APOE ε4 +/−No.194NANA2NA
 APOE ε4 +/+No.101NANANANA
Blood and CSF samplesNo.4012NA2114NA
Blood samples onlyNo.58950NA1419
Biochemical
 Aβ42 (pg/mL)Median (IQR)504 (424–652)745 (489 to 1191)NA1034 (917–1225)1093 (823–1248)NA
 T-tau (pg/mL)Median (IQR)627 (409–920)382 (243 to 683)NA215 (171–328)174 (117–272)NA
 P-tau (pg/mL)Median (IQR)89 (67–117)56 (43 to 83)NANA39 (29–45)NA
 Aβ42//Aβ40-ratioMedian (IQR)0.5 (0.4–0.7)0.7 (0.5 to 1.0)NANA1.0 (0.8–1.2)NA
 Albumin CSF/blood ratioMedian (IQR)5.9 (4.3–7.2)6.6 (5.3 to 9.0)NA6.1 (5.0–6.9)7.1 (5.2–9.3)NA
  • Demographic, genetic and biochemical data are shown for every diagnostic group. Control patients are further subdivided into healthy volunteers, patients with tension-type headaches, patients with psychiatric diagnoses, namely affective disorders (n=24), neurotic or stress related disorders (n=1), or schizophrenia (n=3), or patients with Parkinson’s disease (PD).

  • AD, Alzheimer’s disease; Aβ42 or 40, β-amyloid 42 or 40; CON, controls; CSF, cerebrospinal fluid; Headache, patients with tension-type headache; Healthy, healthy volunteers; IQR, interquartile range; MCI, mild cognitive impairment due to AD; MMSE, mini mental state examination; MoCA, Montreal Cognitive Assessment; NA, not available; PD, patients with Parkinson’s disease; Psychiatric, patients with psychiatric diagnoses; P-tau, phosphorylated tau; T-tau, total tau.